Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Biohaven Pharmaceutical Holding Company Ltd (BHVN)

Biohaven Pharmaceutical Holding Company Ltd (BHVN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,983,927
  • Shares Outstanding, K 59,939
  • Annual Sales, $ 0 K
  • Annual Income, $ -528,810 K
  • 60-Month Beta 1.09
  • Price/Sales 165.62
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade BHVN with:

Options Overview

Details
  • Implied Volatility 65.56%
  • Historical Volatility 37.43%
  • IV Percentile 20%
  • IV Rank 7.73%
  • IV High 208.95% on 03/16/20
  • IV Low 53.54% on 09/18/20
  • Put/Call Vol Ratio 0.04
  • Today's Volume 501
  • Volume Avg (30-Day) 331
  • Put/Call OI Ratio 0.60
  • Today's Open Interest 12,475
  • Open Int (30-Day) 16,488

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -2.89
  • Number of Estimates 6
  • High Estimate -2.23
  • Low Estimate -3.28
  • Prior Year -2.85
  • Growth Rate Est. (year over year) -1.40%

Price Performance

See More
Period Period Low Period High Performance
1-Month
76.64 +10.88%
on 02/23/21
93.54 -9.15%
on 01/27/21
-3.80 (-4.28%)
since 01/26/21
3-Month
75.00 +13.31%
on 01/19/21
95.00 -10.55%
on 12/21/20
-4.64 (-5.18%)
since 11/25/20
52-Week
26.56 +219.95%
on 03/17/20
100.77 -15.67%
on 11/18/20
+40.35 (+90.41%)
since 02/26/20

Most Recent Stories

More News
Biohaven To Report Fourth Quarter And Full Year 2020 Financial Results And Recent Business Developments On March 1, 2021

, /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological...

BHVN : 84.98 (+2.20%)
Why Biohaven (BHVN) Might Surprise This Earnings Season

Biohaven (BHVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

BHVN : 84.98 (+2.20%)
Biohaven's BHV-1200, A Multimodal Antibody Therapy Enhancer (MATE), Demonstrates Effective Neutralization Of Multiple Strains Of COVID-19

, /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates, today announced...

BHVN : 84.98 (+2.20%)
Cassava (SAVA) Rises on Late-Stage Alzheimer's Study Plans

Cassava (SAVA) provides outline for future study plans on its Alzheimer's disease candidate, simufilam.

BIIB : 272.88 (-1.58%)
PFE : 33.49 (-0.98%)
BHVN : 84.98 (+2.20%)
SAVA : 48.58 (-4.52%)
Biohaven Provides Update On ESG Practices

, /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company" or "Biohaven"), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates today...

BHVN : 84.98 (+2.20%)
Cassava (SAVA) Soars on Encouraging Alzheimer's Study Data

Cassava's (SAVA) Alzheimer's disease candidate, simufilam, improved cognition and behavior scores following six months of treatment in an open-label clinical study.

BIIB : 272.88 (-1.58%)
PFE : 33.49 (-0.98%)
BHVN : 84.98 (+2.20%)
SAVA : 48.58 (-4.52%)
Frazier Healthcare Partners Adds Highly Experienced Investor to Life Sciences Team

Frazier Healthcare Partners announced the planned addition of Albert Cha, M.D., Ph.D. as Managing Partner on the Life Sciences team. He has over 20 years of experience investing in public and private biopharmaceutical...

AGN : 193.02 (+0.02%)
ASND : 154.97 (-2.33%)
KALV : 32.87 (-1.05%)
ACRS : 22.28 (+5.00%)
BHVN : 84.98 (+2.20%)
MNLO : 1.3500 (-2.17%)
SRRA : 14.74 (+1.83%)
BIOD : 0.65 (+6.56%)
Biohaven Announces Preliminary 4Q2020 Net Product Revenue For NURTEC® ODT

, /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company" or "Biohaven"), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates today...

BHVN : 84.98 (+2.20%)
Biotech Stock Roundup: ALXN Pauses Study, ACRS & GRTS Surge, & Other Updates

The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Alexion (ALXN), Aclaris (ACRS) and Biohaven (BHVN).

ALXN : 152.75 (-0.59%)
LXRX : 7.19 (-3.88%)
ACRS : 22.28 (+5.00%)
BHVN : 84.98 (+2.20%)
GRTS : 13.57 (+2.26%)
Biohaven (BHVN) Falls as Troriluzole Fails in Alzheimer's Study

Biohaven (BHVN) announces preliminary data from a phase II/III AD study demonstrating troriluzole's failure to achieve statistical improvement in primary endpoints.

BIIB : 272.88 (-1.58%)
PFE : 33.49 (-0.98%)
MRK : 72.62 (-2.68%)
BHVN : 84.98 (+2.20%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. It focuses on the identification and development of orphan neurologic indications and other neurological pathways. The company's pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which...

See More

Key Turning Points

3rd Resistance Point 91.40
2nd Resistance Point 88.87
1st Resistance Point 86.92
Last Price 84.98
1st Support Level 82.45
2nd Support Level 79.92
3rd Support Level 77.97

See More

52-Week High 100.77
Last Price 84.98
Fibonacci 61.8% 72.42
Fibonacci 50% 63.66
Fibonacci 38.2% 54.91
52-Week Low 26.56

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar